

OLIVER KLEIN

**Group Leader Technology Development Unit Tissue Typing Nominee
Non-Voting Member**



BIH Regeneration
BIH Center for Regenerative Therapies (BCRT)




Scientific Evolution



“Analytics”

2007*- Charité/BCRT- *Proteomics Unit/Tissue Typing*
2003 - Employee at FMP Berlin *NMR, Drug Screening*
2002 - Pharmaceutical-Chemical Engineering
1999 - Chemisch technischer Assistent

Expertise



- ❖ *Proteomics for clinical Applications*
- ❖ *Signature driven spatial OMICS (Proteomics, Metabolomics Glycomics) to aid the development of diagnostic/prognostic tools*
- ❖ *Characterization of therapeutic cell product, biomaterials and patient derived materials*
- ❖ *Member of the BIH Multi OMICS HUB 2019/2020*

Projects Highlights

BMBF MSTAR- local research core for mass spectrometry in systems medicine to develop prognostic markers

EU-Reshape- Applying and evolution of next-generation Treg approaches

BIH-CRG-Terminat NB-Deeper understanding of signaling networks driving neuroblastoma treatment


Pfizer Aspire- In situ diagnostic for transthyretin amyloidosis stratification in heart failure using imaging MS

OLIVER KLEIN

Group Leader Technology Development Unit Tissue Typing Nominee
Non-Voting Member



BIH Regeneration
BIH Center for Regenerative Therapies (BCRT)



REINFORCE CLINICAL TRANSLATION PROJECTS

Conducting translational and clinical studies together with partners from other BIH-FOCUS Areas and HUBs (BIH fund accumulation->BCRT)



INTEGRATION-MULTI OMICS IN CLINICAL STUDIES

Design/Planning the cooperation with BIH-HUBs MULTI OMICS and CLINICAL TRANSLATION



HEALTHCARE AND TECHNOLOGY

PRACTICAL COURSES and SEMINAR SERIES to improve interaction between clinicians, basic and technology-based scientists

“I would like to contribute to the shaping of the BCRT in the BIH”